Youn H Kim

Summary

Affiliation: Stanford University
Country: USA

Publications

  1. ncbi request reprint Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach
    Steven M Horwitz
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 6:436-42. 2008
  2. doi request reprint Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome
    Denise K Woo
    Department of Dermatology, Stanford University, Stanford, CA 94305, USA
    Arch Dermatol 145:667-74. 2009
  3. doi request reprint Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin
    Youn H Kim
    Stanford Cancer Center, Stanford, CA, USA
    Leuk Lymphoma 54:284-9. 2013
  4. pmc In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
    Youn H Kim
    Department of Dermatology, Stanford University School of Medicine, CA, USA
    Blood 119:355-63. 2012
  5. ncbi request reprint Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
    Youn H Kim
    Multidisciplinary Cutaneous Lymphoma Program, Stanford Comprehensive Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Blood 109:4655-62. 2007
  6. ncbi request reprint Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience
    Youn H Kim
    Department of Dermatology, Stanford University School of Medicine, 900 Blake Wilbur Dr, No W0069, Stanford, CA 94305, USA
    Arch Dermatol 139:165-73. 2003
  7. ncbi request reprint Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
    Youn H Kim
    Department of Dermatology, Multidisciplinary Cutaneous Lymphoma Program, Stanford Cancer Center, Stanford, California 94305, USA
    J Am Acad Dermatol 63:975-83. 2010
  8. ncbi request reprint TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Resear
    Youn H Kim
    Department of Dermatology, Stanford Comprehensive Cancer Center, Stanford, CA 94305, USA
    Blood 110:479-84. 2007
  9. ncbi request reprint Management with topical nitrogen mustard in mycosis fungoides
    Youn H Kim
    Department of Dermatology, Multidisciplinary Cutaneous Lymphoma Group, Stanford University School of Medicine, Stanford, California 94305, USA
    Dermatol Ther 16:288-98. 2003
  10. ncbi request reprint Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma
    Wen Kai Weng
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Sci Transl Med 5:214ra171. 2013

Detail Information

Publications40

  1. ncbi request reprint Review of the treatment of mycosis fungoides and sézary syndrome: a stage-based approach
    Steven M Horwitz
    Memorial Sloan Kettering Cancer Center, New York, New York 10021, USA
    J Natl Compr Canc Netw 6:436-42. 2008
    ..Many milder therapies may be repeated several times in the disease course, and maintenance and tapering strategies are common. This article also discusses the emerging role of allogeneic stem cell transplantation...
  2. doi request reprint Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome
    Denise K Woo
    Department of Dermatology, Stanford University, Stanford, CA 94305, USA
    Arch Dermatol 145:667-74. 2009
    ....
  3. doi request reprint Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin
    Youn H Kim
    Stanford Cancer Center, Stanford, CA, USA
    Leuk Lymphoma 54:284-9. 2013
    ..Median time to CMRP was 1.8 months, and median duration of CMRP was 5.6 months. Study results suggest that the clinical benefit of romidepsin may extend beyond objective responses...
  4. pmc In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study
    Youn H Kim
    Department of Dermatology, Stanford University School of Medicine, CA, USA
    Blood 119:355-63. 2012
    ..This study is registered at www.clinicaltrials.gov as NCT00226993...
  5. ncbi request reprint Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma
    Youn H Kim
    Multidisciplinary Cutaneous Lymphoma Program, Stanford Comprehensive Cancer Center, 875 Blake Wilbur Drive, Stanford, CA 94305, USA
    Blood 109:4655-62. 2007
    ..The treatment was well tolerated with no dose-related toxicity other than the targeted depletion of peripheral T cells. A pivotal study has been initiated based on these findings...
  6. ncbi request reprint Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience
    Youn H Kim
    Department of Dermatology, Stanford University School of Medicine, 900 Blake Wilbur Dr, No W0069, Stanford, CA 94305, USA
    Arch Dermatol 139:165-73. 2003
    ..To evaluate and update the response and survival outcomes and toxic effects in patients treated with topical nitrogen mustard (mechlorethamine hydrochloride) as primary therapy...
  7. ncbi request reprint Phase I trial of a Toll-like receptor 9 agonist, PF-3512676 (CPG 7909), in patients with treatment-refractory, cutaneous T-cell lymphoma
    Youn H Kim
    Department of Dermatology, Multidisciplinary Cutaneous Lymphoma Program, Stanford Cancer Center, Stanford, California 94305, USA
    J Am Acad Dermatol 63:975-83. 2010
    ..PF-3512676 (formerly CPG 7909) is a Toll-like receptor 9 agonist that is being investigated for treatment of patients with advanced cancer...
  8. ncbi request reprint TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Resear
    Youn H Kim
    Department of Dermatology, Stanford Comprehensive Cancer Center, Stanford, CA 94305, USA
    Blood 110:479-84. 2007
    ..Due to the clinical and pathologic heterogeneity of the cutaneous lymphomas, the currently proposed TNM system is meant to be primarily an anatomic documentation of disease extent and not to be used as a prognostic guide...
  9. ncbi request reprint Management with topical nitrogen mustard in mycosis fungoides
    Youn H Kim
    Department of Dermatology, Multidisciplinary Cutaneous Lymphoma Group, Stanford University School of Medicine, Stanford, California 94305, USA
    Dermatol Ther 16:288-98. 2003
    ..Topical NM is used safely in pediatric patients and there is no evidence of any clinically significant systemic absorption of topically applied NM...
  10. ncbi request reprint Minimal residual disease monitoring with high-throughput sequencing of T cell receptors in cutaneous T cell lymphoma
    Wen Kai Weng
    Division of Blood and Marrow Transplantation, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
    Sci Transl Med 5:214ra171. 2013
    ..We have thus demonstrated the utility of TCRB HTS to assess MRD with increased sensitivity and specificity compared to other current methodologies, and to monitor response to therapy in this MF/SS patient population. ..
  11. pmc In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study
    Joshua D Brody
    269 Campus Dr CCSR rm 1105, Stanford, CA 94305, USA
    J Clin Oncol 28:4324-32. 2010
    ..In a preclinical lymphoma model, intratumoral injection of a Toll-like receptor 9 (TLR9) agonist induced systemic antitumor immunity and cured large, disseminated tumors...
  12. doi request reprint Clinicopathologic features and treatment outcomes in Woringer-Kolopp disease
    Juliette Lee
    Department of Dermatology, Stanford University School of Medicine, Stanford, California 94305, USA
    J Am Acad Dermatol 59:706-12. 2008
    ..Our observations confirm that Woringer-Kolopp disease carries an excellent prognosis, and support that the most effective and appropriate treatment for recalcitrant or severe Woringer-Kolopp disease is localized radiation therapy...
  13. pmc Combined use of PCR-based TCRG and TCRB clonality tests on paraffin-embedded skin tissue in the differential diagnosis of mycosis fungoides and inflammatory dermatoses
    Bing Zhang
    Department of Pathology, L235, Stanford University Medical Center, Stanford, CA 94305, USA
    J Mol Diagn 12:320-7. 2010
    ..Combined use of the two tests in patients with intermediate pretest probabilities as proposed in the algorithm could improve test utility...
  14. doi request reprint A phase II study of SGN-30 in cutaneous anaplastic large cell lymphoma and related lymphoproliferative disorders
    Madeleine Duvic
    Department of Dermatology, University of Texas MD Anderson Cancer Center, Houston, Texas 77030 4003, USA
    Clin Cancer Res 15:6217-24. 2009
    ....
  15. ncbi request reprint Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression
    Youn H Kim
    Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Arch Dermatol 139:857-66. 2003
    ..To study and update the clinical characteristics and long-term outcome of our patients with mycosis fungoides (MF) and Sézary syndrome (SS), and to identify important clinical factors predictive of survival and disease progression...
  16. doi request reprint Multicenter phase II trial of enzastaurin in patients with relapsed or refractory advanced cutaneous T-cell lymphoma
    Christiane Querfeld
    Department of Dermatology, Northwestern University, Chicago, IL 60611, USA
    Leuk Lymphoma 52:1474-80. 2011
    ..Enzastaurin was well tolerated with mostly grade 1-2 adverse events, mainly diarrhea and fatigue. There were two adverse event-related drug discontinuations with one possibly treatment-related...
  17. doi request reprint Clonal identity and differences in primary cutaneous B-cell lymphoma occurring at different sites or time points in the same patient
    Mika Fujiwara
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305 5324, USA
    Am J Dermatopathol 35:11-8. 2013
    ..Although the study is small and the results need to be confirmed in a larger study, these findings suggest that a subset of PCBCL at different sites may represent different primary tumors rather than occurrence of a single disease...
  18. doi request reprint Intravascular ALK-negative anaplastic large cell lymphoma with localized cutaneous involvement and an indolent clinical course: toward recognition of a distinct clinicopathologic entity
    Ryan A Metcalf
    Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Am J Surg Pathol 37:617-23. 2013
    ....
  19. doi request reprint The frequency of dual TCR-PCR clonality in granulomatous disorders
    Salma Dabiri
    Department of Pathology, Stanford University Medical Center, Stanford, CA 94305, USA
    J Cutan Pathol 38:704-9. 2011
    ..The frequency of T-cell clonality in association with granulomatous dermatitides has not yet been established...
  20. ncbi request reprint Quality-of-life improvements in cutaneous T-cell lymphoma patients treated with denileukin diftitox (ONTAK)
    Madeleine Duvic
    Department of Dermatology, University of Texas, M D Anderson Cancer Center, Houston, TX 77030, USA
    Clin Lymphoma 2:222-8. 2002
    ..Heavily pretreated patients with advanced and/or recurrent CTCL who responded to denileukin diftitox therapy showed significant improvements in self-rated overall QOL, skin appearance, and pruritus severity...
  21. doi request reprint Evaluation of B-cell clonality using the BIOMED-2 PCR method effectively distinguishes cutaneous B-cell lymphoma from benign lymphoid infiltrates
    Anjali V Morales
    Department of Dermatology, Stanford University Medical Center, Stanford, CA 94305, USA
    Am J Dermatopathol 30:425-30. 2008
    ..This study forms the basis for further investigating the role of Ig clonality in distinguishing CBCL from benign lymphoid infiltrates that may pose a challenge in morphologic diagnosis...
  22. pmc Transcriptome sequencing in Sezary syndrome identifies Sezary cell and mycosis fungoides-associated lncRNAs and novel transcripts
    CAROLYN S LEE
    Programs in Epithelial Biology, Department of Dermatology, Stanford University, CA, USA
    Blood 120:3288-97. 2012
    ..Our findings characterize the SS transcriptome and support recent reports that implicate lncRNA dysregulation in human malignancies...
  23. doi request reprint The Stanford University experience with conventional-dose, total skin electron-beam therapy in the treatment of generalized patch or plaque (T2) and tumor (T3) mycosis fungoides
    Daniel Navi
    Department of Dermatology, Stanford University, Stanford, CA, USA
    Arch Dermatol 147:561-7. 2011
    ....
  24. ncbi request reprint Cytologic evaluation of lymphadenopathy associated with mycosis fungoides and Sezary syndrome: role of immunophenotypic and molecular ancillary studies
    Reetesh K Pai
    Department of Pathology, Stanford University, Stanford, California 94305, USA
    Cancer 114:323-32. 2008
    ..With fine-needle aspiration biopsy, material can be collected for ancillary diagnostic studies and for morphologic evaluation...
  25. doi request reprint Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab
    Anjali V Morales
    Multidisciplinary Cutaneous Lymphoma Program, Stanford Comprehensive Cancer Center, Stanford, California 94305, USA
    J Am Acad Dermatol 59:953-7. 2008
    ..Rituximab is a chimeric monoclonal IgG1 antibody directed against the CD20 antigen of B cells. Clinical efficacy of systemic rituximab in CBCL has yet to be established...
  26. ncbi request reprint Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome: evidence from population-based and clinical cohorts
    Kathie P Huang
    Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Arch Dermatol 143:45-50. 2007
    ..To assess risks for developing second malignancies in patients with mycosis fungoides or Sézary syndrome...
  27. ncbi request reprint CD30+ cutaneous lymphoproliferative disorders: the Stanford experience in lymphomatoid papulosis and primary cutaneous anaplastic large cell lymphoma
    Howard L Liu
    Department of Dermatology, Stanford University, 900 Blake Wilbur Drive, Stanford, CA 94305, USA
    J Am Acad Dermatol 49:1049-58. 2003
    ..Prior studies have shown CD30+CLPDs have an excellent prognosis...
  28. ncbi request reprint Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography
    Eunice Y Tsai
    Department of Dermatology, Stanford University School of Medicine, Stanford, Calif, USA
    Arch Dermatol 142:577-84. 2006
    ..To evaluate the usefulness of integrated positron emission tomography and computed tomography (PET/CT) in staging mycosis fungoides (MF) and Sézary syndrome and to correlate PET/CT data with histopathologic diagnosis of lymph nodes (LNs)...
  29. pmc The histone deacetylase inhibitor, romidepsin, suppresses cellular immune functions of cutaneous T-cell lymphoma patients
    Michael J Kelly-Sell
    Department of Dermatology, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA 19104, USA
    Am J Hematol 87:354-60. 2012
    ..05). These findings raise concern that HDACis suppress immune function in CTCL patients and they support the concurrent use of multiple immune stimulatory agents to preserve the host immune response...
  30. ncbi request reprint Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology
    Anu G Jayaraman
    Department of Pathology, Stanford University Medical Center, Stanford, California 94305 5324, USA
    J Cutan Pathol 33:6-11. 2006
    ....
  31. ncbi request reprint Clinical and pathological features of posttransplantation lymphoproliferative disorders presenting with skin involvement in 4 patients
    David P Beynet
    Department of Dermatology, Stanford University School of Medicine, Stanford, CA 94305, USA
    Arch Dermatol 140:1140-6. 2004
    ..Although extranodal involvement in PTLD is common, cutaneous presentation is rare, with only 19 cases reported previously...
  32. ncbi request reprint Gene expression profiles of cutaneous B cell lymphoma
    Monique N Storz
    Department of Pathology, Division of Medical Oncology, Stanford University Medical Center, Stanford, California 94305, USA
    J Invest Dermatol 120:865-70. 2003
    ....
  33. ncbi request reprint T-cell clonality analysis in biopsy specimens from two different skin sites shows high specificity in the diagnosis of patients with suggested mycosis fungoides
    Stacy E Thurber
    Department of Pathology, Stanford University, Stanford, California 94035, USA
    J Am Acad Dermatol 57:782-90. 2007
    ....
  34. ncbi request reprint European Organization for Research and Treatment of Cancer and International Society for Cutaneous Lymphoma consensus recommendations for the management of cutaneous B-cell lymphomas
    Nancy J Senff
    Department of Dermatology, Leiden University Medical Center, Leiden, The Netherlands
    Blood 112:1600-9. 2008
    ..They may therefore contribute to uniform staging and treatment and form the basis for future clinical trials in patients with a CBCL...
  35. ncbi request reprint Prognosis, clinical outcomes and quality of life issues in cutaneous T-cell lymphoma
    Marie France Demierre
    Department of Dermatology and Medicine, Boston University School of Medicine, 720 Harrison Avenue, DOB 801A, Boston, MA 02118, USA
    Hematol Oncol Clin North Am 17:1485-507. 2003
    ..Nevertheless, physicians who are caring for patients who have advanced MF/SS should acknowledge the spiritual dimension as an integral component of the dying process...
  36. ncbi request reprint Interstitial mycosis fungoides, a variant of mycosis fungoides resembling granuloma annulare and inflammatory morphea
    Lyndon D Su
    Department of Pathology, University of Michigan, Ann Arbor, Michigan, USA
    J Cutan Pathol 29:135-41. 2002
    ..Interstitial mycosis fungoides (IMF) is a rare variant of mycosis fungoides that resembles the interstitial form of granuloma annulare and inflammatory morphea. IMF has received little attention in the literature...
  37. ncbi request reprint Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma
    Elise A Olsen
    Duke University, Durham, NC, USA
    J Clin Oncol 25:3109-15. 2007
    ....
  38. doi request reprint Expression of HGAL in primary cutaneous large B-cell lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma
    Xiuyan Xie
    Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH 44195, USA
    Mod Pathol 21:653-9. 2008
    ..Characterizing PCLBCLs with markers of B-cell maturation stage is a useful framework for studying, classifying, and clinically stratifying these lymphomas...
  39. ncbi request reprint Non-Hodgkin's lymphomas
    Andrew D Zelenetz
    J Natl Compr Canc Netw 6:356-421. 2008
  40. ncbi request reprint Bexarotene gel: a Food and Drug Administration-approved skin-directed therapy for early-stage cutaneous T-cell lymphoma
    Howard L Liu
    Arch Dermatol 138:398-9. 2002